GUANADREL

US Previously Marketed

First approved in 1982

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H19N3O2
Molecular Weight	213.2768
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)NCC1COC2(CCCCC2)O1

InChI

InChIKey=HPBNRIOWIXYZFK-UHFFFAOYSA-N

InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00226
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cons/guanadrel.html

Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the norepinephrine pump or transporter. Guanadrel slowly displaces norepinephrine from its storage in nerve endings and thereby blocks the release of norepinephrine normally produced by nerve stimulation. The reduction in neurotransmitter release in response to sympathetic nerve stimulation, as a result of catecholamine depletion, leads to reduced arteriolar vasoconstriction, especially the reflex increase in sympathetic tone that occurs with a change in position. Guanadrel is used to treat and control hypertension.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Norepinephrine transporter 191 Target ID: CHEMBL222 Sources: http://www.drugbank.ca/drugs/DB00226	Partial Agonist 290
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D00607	Agonist 2678
Adrenergic receptor alpha-2 113 Target ID: CHEMBL2095158 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D00607	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.drugs.com/cons/hylorel.html	Primary		Approved 8429	Hylorel Approved Use Used to treat high blood pressure (hypertension). Launch Date 1982

C_max

Value	Dose	Analyte	Population
28.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243808	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
73 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
404.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243808	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
234 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
627 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	GUANADREL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		GUANADREL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2715368	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		GUANADREL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
150 mg 1 times / day steady, oral Highest studied dose Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4571980	unhealthy, 41 years (range: 17 - 68 years) n = 21 Health Status: unhealthy Condition: hypertension Age Group: 41 years (range: 17 - 68 years) Sex: M+F Population Size: 21 Sources: https://pubmed.ncbi.nlm.nih.gov/4571980	Sources: https://pubmed.ncbi.nlm.nih.gov/4571980
40 mg 1 times / day multiple, oral Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4031111	unhealthy, 54 years (range: 43 - 64 years) Health Status: unhealthy Condition: hypertension Age Group: 54 years (range: 43 - 64 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4031111	Disc. AE: Urinary incontinence... AEs leading to discontinuation/dose reduction: Urinary incontinence (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4031111

AEs

AE	Significance	Dose	Population
Urinary incontinence	1 patient Disc. AE	40 mg 1 times / day multiple, oral Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4031111	unhealthy, 54 years (range: 43 - 64 years) Health Status: unhealthy Condition: hypertension Age Group: 54 years (range: 43 - 64 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4031111

Sourcing

Vendor/Aggregator	ID	URL
AHH Chemical co.,ltd	MR-1013811	http://www.ahhchemical.com/product/MR-1013811.html
Ambinter	Amb22734802	http://www.ambinter.com/reference/22734802
BLD Pharm	BD132426	http://www.bldpharm.com/products/40580-59-4.html
ChemMol	99086834	http://www.chemmol.com/chemmol/99086834.html
Excenen	EX-A4513	https://www.excenen.com/searchresultlist.php?id=EX-A4513
Finetech	FT-0669066	http://www.finetechnology-ind.com/prod/detail/pub/22195-34-2.html
Sinfoo Biotech	S061878	http://www.sinfoobiotech.com/product/1065296
Smolecule	S567493	https://www.smolecule.com/products/s567493
THE BioTek	bt-308688	https://www.thebiotek.com/product/others/bt-308688
mcule	MCULE-3794032460	https://mcule.com/MCULE-3794032460/

PubMed

Title	Date	PubMed
Comparison of guanadrel and guanethidine efficacy and side effects.	1983	6850722
N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors.	2001 Sep 3	11527735
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

For high blood pressure: Adults—At first, 5 milligrams (mg) two times a day. Then, may be increased up to 20 to 75 mg a day, divided into two to four doses.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

GUANADREL

Official Name

English

guanadrel [INN]

Common Name

English

Guanadrel [WHO-DD]

Common Name

English

GUANIDINE (1,4-DIOXASPIRO(4.5)DEC-2-YLMETHYL)-

Common Name

English

GUANADREL [VANDF]

Common Name

English

GUANADREL [MI]

Common Name

English

(1,4-DIOXASPIRO(4.5)DEC-2-YLMETHYL)GUANIDINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C270

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

Code System Code Type Description

FDA UNII

765C9332T4

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

MESH

C004945

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

DRUG CENTRAL

1339

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

CAS

40580-59-4

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

IUPHAR

7193

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

ChEMBL

CHEMBL1037

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

NCI_THESAURUS

C65827

Created by admin on Fri Dec 15 16:21:26 GMT 2023 , Edited by admin on Fri Dec 15 16:21:26 GMT 2023

PRIMARY

MERCK INDEX

m5864

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

Merck Index

PUBCHEM

38521

Created by admin on Fri Dec 15 16:21:26 GMT 2023 , Edited by admin on Fri Dec 15 16:21:26 GMT 2023

PRIMARY

EVMPD

SUB07980MIG

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

CHEBI

5555

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

EPA CompTox

DTXSID2048533

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

INN

2590

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

DRUG BANK

DB00226

Created by admin on Fri Dec 15 16:21:25 GMT 2023 , Edited by admin on Fri Dec 15 16:21:25 GMT 2023

PRIMARY

SMS_ID

100000084471

Created by admin on Fri Dec 15 16:21:26 GMT 2023 , Edited by admin on Fri Dec 15 16:21:26 GMT 2023

PRIMARY

RXCUI

26296

Created by admin on Fri Dec 15 16:21:26 GMT 2023 , Edited by admin on Fri Dec 15 16:21:26 GMT 2023

PRIMARY

RxNorm

WIKIPEDIA

GUANADREL

Created by admin on Fri Dec 15 16:21:26 GMT 2023 , Edited by admin on Fri Dec 15 16:21:26 GMT 2023

PRIMARY

ACTIVE MOIETY


					765C9332T4

GUANADREL

SALT/SOLVATE (PARENT)


					MT147RMO91

GUANADREL SULFATE

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00226Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cons/guanadrel.html

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00226
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cons/guanadrel.html

C_max

T_1/2